NCT00220584View on ClinicalTrials.gov

An Open-Label Trial of Donepezil in Fragile X Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Fragile X Syndrome
Interventions
DRUG

donepezil

donepezil 5 mg daily for 3 weeks (days 1-21); 10 mg daily for 3 weeks (days 22-42)

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT00220584 - An Open-Label Trial of Donepezil in Fragile X Syndrome | Biotech Hunter | Biotech Hunter